AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7799581
Drug: Combined endolymphatic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endolymphatic therapy (lymph irradiation with helium-neon laser and direct endolymphatic antibacterial therapy)
Trial: 3287907
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg
Trial: 31455324
Drug: Mobile outreach
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile outreach team treatment (DOTS regime)
Trial: 31455324
Drug: Facility-based DOTS
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facility-based DOTS treatment
Trial: 31455324
Drug: Mobile outreach
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile outreach team treatment
Trial: 22747323
Drug: RRGICB (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRGICB (combination of RRGI and CB)
Trial: 21309489
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at target effect-site concentration (Ce) of 0.5 ng/ml
Trial: 21309489
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at target effect-site concentration (Ce) of 1 ng/ml
Trial: 21309489
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at target effect-site concentration (Ce) of 2 ng/ml
Trial: 21309489
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at target effect-site concentration (Ce) of 4 ng/ml
Trial: 10542978
Drug: Calibration with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calibration with a 3000 ml syringe
Trial: 106982
Drug: 5 antiinflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 antiinflammatory drugs
Trial: 30428049
Drug: Pimodivir 300
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimodivir 300 mg
Trial: 30098042
Drug: Pimodivir 600
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimodivir 600 mg
Trial: 30428049
Drug: Pimodivir 600
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimodivir 600 mg plus Oseltamivir 75 mg
Trial: 26739013
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive medication
Trial: 18575277
Drug: 100-g OGTT
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-g OGTT
Trial: 15909229
Drug: Omnilux Revive
RxNorm normalized name: carboxymethylcellulose sodium Ophthalmic Solution [Revive Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnilux Revive facial treatment (20 min treatments, three times a week for three weeks)
Trial: 15909229
Drug: Omnilux Revive
RxNorm normalized name: carboxymethylcellulose sodium Ophthalmic Solution [Revive Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnilux Revive facial treatment
Trial: 12217597
Drug: Infliximab 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab 5mg/kg IV + Prednisone 40 mg/day for 28 days
Trial: 12217597
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Prednisone 40 mg/day for 28 days
Trial: 7779142
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg t.i.d.) and Indometacin (25 mg b.i.d.)
Trial: 6253067
Drug: Cyclophosphamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (600 mg/m2 every 3 weeks)
Trial: 6253067
Drug: Cyclophosphamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (600 mg/m2 every 3 weeks) and CCNU (70 mg/m2 every 6 weeks)
Trial: 6253067
Drug: Cyclophosphamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (600 mg/m2 every 3 weeks), CCNU (70 mg/m2 every 6 weeks), and doxorubicin (40 mg/m2 every 3 weeks)
Trial: 19351731
Drug: l-arginine/GHRH infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine/GHRH infusion
Trial: 19351731
Drug: l-arginine/GHRP-2 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine/GHRP-2 infusion
Trial: 18843793
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein restriction (0.95 g kg(‐1) of body weight per day) for 3 weeks
Trial: 12409984
Drug: Fasudil 5
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 5 mg TID
Trial: 12409984
Drug: Fasudil 10
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 10 mg TID
Trial: 12409984
Drug: Fasudil 20
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 20 mg TID
Trial: 12409984
Drug: Fasudil 40
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Fasudil 40 mg TID
Trial: 12409984
Drug: Fasudil (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasudil (various doses)
Trial: 409315
Drug: Cromolyn sodium,
RxNorm normalized name: Cromolyn Sodium, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium, administered for four weeks
Trial: 31399275
Drug: Adjuvanted 0.5
RxNorm normalized name: anthrax vaccine adsorbed, adjuvanted 0.5 mL/dose INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted 0.5 μg total viral protein (TP) with Al(OH)3
Trial: 31399275
Drug: Adjuvanted 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted 1.0 μg total viral protein (TP) with Al(OH)3
Trial: 31399275
Drug: Non-adjuvanted 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted 1.0 μg total viral protein (TP)
Trial: 29229209
Drug: AV-101 (l-4-chlorokynurenine)
RxNorm normalized name: 4-hydroxy-L-phenylalanine
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (l-4-chlorokynurenine) at doses of 30-1800mg (Phase 1A) and 360, 1080, 1440mg/day (Phase 1B) administered orally for 14 days.
Trial: 29229209
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally for 14 days.
Trial: 23241479
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and implant naltrexone
Trial: 19593797
Drug: R-CHOP +
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP + bortezomib (Arm A: 1 mg/m²; Arm B: 1.3 mg/m²)
Trial: 19593797
Drug: R-CHOP +
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP + bortezomib (Arm A: 1.3 mg/m²; Arm B: 1.6 mg/m²)
Trial: 15119909
Drug: Extended-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release carbamazepine (ERC-CBZ) at a mean dose of 756.44 mg/day
Trial: 8112490
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (general)
Trial: 2467135
Drug: Amlodipine 2.5-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5-5.0 mg (medium-dose group)
Trial: 2467135
Drug: Amlodipine 5.0-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 5.0-10.0 mg (high-dose group)
Trial: 2467135
Drug: Amlodipine 1.25-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 1.25-2.5 mg (low-dose group)
Trial: 17072702
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg oral clonidine and 20 mg raftidine (clonidine group; n = 41)
Trial: 17072702
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg raftidine only (control group; n = 41)
Trial: 14574247
Drug: Implant technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant technique of scleral buckling
Trial: 14574247
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant and explant techniques
Trial: 10997364
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 100,000 IU vitamin A
Trial: 8959519
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.i.d.) plus Amoxycillin (750 mg t.i.d.) for 2 weeks
Trial: 8959519
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg b.i.d.) plus Clarithromycin (500 mg t.i.d.) for 2 weeks
Trial: 8959519
Drug: Second consecutive
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second consecutive dual therapy (either omeprazole plus amoxycillin or omeprazole plus clarithromycin)
Trial: 1526681
Drug: Cefodizime (CDZ)
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (CDZ) 1 g i.m. b.i.d. for eight days
Trial: 4089792
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (Hep)
Trial: 4089792
Drug: Heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin + dihydroergotamine (DHE-Hep)
Trial: 4089792
Drug: Heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin + sulphinpyrazone (Sulph-Hep)
Trial: 24113340
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-frequency repetitive transcranial magnetic stimulation and traditional eye-hand integration training
Trial: 18195202
Drug: Ergocalciferol, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol, 1000 IU/d, plus calcium citrate, 1000 mg/d
Trial: 18195202
Drug: Calcium citrate,
RxNorm normalized name: calcium citrate, calcium malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium citrate, 1000 mg/d (control group)
Trial: 15903123
Drug: Alfuzosin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (40 mg)
Trial: 12553387
Drug: Thiopental (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Trial: 12553387
Drug: Thiopental (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (7 mg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Trial: 12553387
Drug: Thiopental (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), cisatracurium (0.1 mg kg(‐1))
Trial: 6222756
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oxytetracycline tablets taken twice daily
Trial: 23615791
Drug: TB‐402 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB‐402 25 mg
Trial: 23615791
Drug: TB‐402 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB‐402 50 mg
Trial: 22058101
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dalfampridine under fasted condition (no food for 10-12 hours)
Trial: 22058101
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dalfampridine under fed condition (after a high-fat meal)
Trial: 15222825
Drug: Implementation intentions
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation intentions for home blood glucose monitoring, 4 times daily for 3 weeks
Trial: 8547077
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of rhIL-3
Trial: 1670783
Drug: Antihistamine-decongestant
RxNorm normalized name: Antihistamine-Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-decongestant
Trial: 28373244
Drug: Intracoronary morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary morphine (3 mg of morphine sulfate diluted with 3 mL of normal saline)
Trial: 28373244
Drug: Control (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (3 mL of normal saline)
Trial: 28373244
Drug: Intracoronary morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary morphine
Trial: 25149705
Drug: CoQ10 100
RxNorm normalized name: Walgreens CoQ10 100mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 100 mg per day (Q100)
Trial: 25149705
Drug: CoQ10 300
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 300 mg per day (Q300)
Trial: 21999406
Drug: Combined perianal-intrarectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined perianal-intrarectal lidocaine-prilocaine cream and lidocaine-ketorolac gel
Trial: 21999406
Drug: Combined perianal-intrarectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block
Trial: 9860085
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg on day 1 decreased to 5 mg on day 7)
Trial: 31331569
Drug: Massage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage with topical 5 ml violet oil for 7 min during six sessions (two weeks)
Trial: 28820681
Drug: Radiofrequency-induced heat
RxNorm normalized name: heather pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency-induced heat therapy (RFHT) at 50°C for 30 seconds
Trial: 28820681
Drug: Intralesional sodium
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional sodium stibogluconate (IL‐SSG) 1-3 mL given weekly until cure/10 doses
Trial: 23167738
Drug: Sealed-capsule irrigation
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealed-capsule irrigation (SCI) using distilled water (DW) for 3 minutes
Trial: 6112526
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg three times a day for 2 weeks
Trial: 6112526
Drug: Metoclopramide 15
RxNorm normalized name: metoclopramide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 15 mg three times a day for 2 weeks
Trial: 6112526
Drug: Metoclopramide (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (any dose)
Trial: 6112526
Drug: Metoclopramide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (5 mg)
Trial: 19073791
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (7 mg/d as multivitamin preparation with ferrous sulfate)
Trial: 19073791
Drug: Placebo (multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (multivitamin preparation without iron)
Trial: 12414860
Drug: 7.5 IU
RxNorm normalized name: Follitropin Alfa 37.5 IU Subcutaneous Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 IU (2.5 mg) GH
Trial: 7629641
Drug: i.v. tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. tubing directly connected to the infusion device
Trial: 17125466
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg) + L-NMMA
Trial: 17125466
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg) + L-NMMA + Fluconazole (0.37 mg.min(‐1).l(‐1))
Trial: 23660571
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) 300 mg·kg‐1 body mass
Trial: 23660571
Drug: Lactate (LACTATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate (LACTATE) 1115 mg
Trial: 20056803
Drug: Sergliflozin etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sergliflozin etabonate (5-500 mg)
Trial: 12570928
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17-beta estradiol (ERT)
Trial: 12570928
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17-beta estradiol combined with continuous 5 mg medroxyprogesterone acetate (HRT)
Trial: 10563646
Drug: Robot training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot training (MIT‐Manus) added to standard rehabilitation treatments
Trial: 1702148
Drug: PVB (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVB (cisplatin 120 mg/m2 day 3, vinblastine 12 mg/m2 day 1, bleomycin 15 U/m2 twice per week)
Trial: 1702148
Drug: VPV (vinblastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPV (vinblastine 8 mg/m2 day 1, cisplatin 120 mg/m2 day 3, VP‐16 50 mg/m2 days 2 to 5)
Trial: 31301135
Drug: Vaccine-encoded adapted
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-encoded adapted epitopes
Trial: 31301135
Drug: Higher HLA-I
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher HLA-I adaptation to the Gag vaccine insert
Trial: 26194728
Drug: Suvorexant 40
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant 40 mg (multiple doses)
Trial: 26194728
Drug: Suvorexant 40
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant 40 mg (single dose)
Trial: 23158943
Drug: CPM combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM combined with Tuina treatment
Trial: 16308382
Drug: Animal facilitated
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal facilitated therapy with dolphins
Trial: 11964641
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL lidocaine (Group A, n=60)
Trial: 11964641
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL lidocaine combined with 1 mL triamcinolone (Group B, n=60)
Trial: 7623251
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac rinse (0.1%) with placebo capsule
Trial: 7623251
Drug: Systemic flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic flurbiprofen (50 mg bid) with placebo rinse
Trial: 7623251
Drug: Placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rinse and capsule
Trial: 2525351
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) before anesthesia
Trial: 2525351
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during anesthesia
Trial: 2525351
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during extracorporeal circulation (ECC)
Trial: 2525351
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution as placebo (control group) before anesthesia
Trial: 2525351
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution as placebo (control group) during anesthesia
Trial: 2525351
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution as placebo (control group) during ECC
Trial: 31013499
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment combined with conventional treatment (treatment group)
Trial: 8607400
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only (control group)
Trial: 27676634
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg oral D2 agonist bromocriptine
Trial: 27676634
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg oral haloperidol
Trial: 24180001
Drug: Combination ART
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ART and maraviroc
Trial: 8856421
Drug: Imipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine treatment (4 weeks duration)
Trial: 1622639
Drug: FEC monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FEC monthly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Trial: 1622639
Drug: FEC weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FEC weekly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Trial: 1622639
Drug: FEC monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FEC monthly
Trial: 1622639
Drug: FEC weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FEC weekly